Cookson Peirce & Co. Inc. Acquires New Holdings in Indivior PLC $INDV

Cookson Peirce & Co. Inc. bought a new position in Indivior PLC (NASDAQ:INDV) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 33,886 shares of the company’s stock, valued at approximately $1,390,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INDV. Quarry LP bought a new stake in shares of Indivior in the 3rd quarter valued at $26,000. Raymond James Financial Inc. bought a new position in Indivior during the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its stake in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares during the period. Rockefeller Capital Management L.P. increased its holdings in shares of Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after acquiring an additional 1,076 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in shares of Indivior in the second quarter worth about $66,000. 60.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Christian Heidbreder sold 18,586 shares of Indivior stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the sale, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. The trade was a 11.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Barclays lowered their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, August 5th. Craig Hallum reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Finally, Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Indivior Price Performance

NASDAQ:INDV opened at $34.87 on Monday. The company has a market cap of $4.12 billion, a P/E ratio of 12.50 and a beta of 0.86. Indivior PLC has a twelve month low of $22.22 and a twelve month high of $42.81. The business has a 50 day moving average price of $39.33 and a two-hundred day moving average price of $36.01.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The company had revenue of $343.00 million for the quarter. As a group, analysts anticipate that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.